IP6K2 is a client for HSP90 and a target for cancer therapeutics development

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 5, 2008, Pages 1389-1390

  Shames, David S ^a,b,c   Minna, John D ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; PROTEIN IP6K2; PROTEIN TYROSINE KINASE; RAF PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INOSITOL HEXAKISPHOSPHATE KINASE; PHOSPHOTRANSFERASE;

CELL HYPOXIA; CELL PH; GENE AMPLIFICATION; NOTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; APOPTOSIS; DRUG DESIGN; HUMAN; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; PHOSPHOTRANSFERASES (PHOSPHATE GROUP ACCEPTOR);

EID: 40349091259     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711993105     Document Type: Note

References (16)